VIVXF (Avivagen) Debt-to-Equity: -0.78 (As of Jul. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Avivagen Debt-to-Equity?

Avivagen VIVXF -99.00% Debt-to-Equity is -0.78 as of Jul. 2023.

Avivagen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $4.65 Mil. Avivagen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2023 was $0.83 Mil. Avivagen's Total Stockholders Equity for the quarter that ended in Jul. 2023 was $-7.01 Mil. Avivagen's debt to equity for the quarter that ended in Jul. 2023 was -0.78.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Avivagen's Debt-to-Equity or its related term are showing as below:

VIVXF's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

Avivagen  (OTCPK:VIVXF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Avivagen Debt-to-Equity Related Terms

Avivagen Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Avivagen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Debt-to-Equity Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.06 -1.41 -1.29 -1.72 -1.02

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.10 -1.02 -0.90 -0.82 -0.78

VIVXF vs DMKPQ, MJNE, ACORQ: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avivagen Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Avivagen's Debt-to-Equity falls into.


Avivagen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Avivagen's Debt to Equity Ratio for the fiscal year that ended in Oct. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.61 + 3.836) / -4.371
=-1.02

Avivagen's Debt to Equity Ratio for the quarter that ended in Jul. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(4.646 + 0.834) / -7.013
=-0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.78 mean?
Avivagen (VIVXF) has a Debt-to-Equity of -0.78 as of Jul. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avivagen and its competitors.
Is Avivagen's Debt-to-Equity too high?
Avivagen's current Debt-to-Equity is -0.78.
How does Avivagen's Debt-to-Equity compare to DMKPQ and MJNE?
Avivagen's Debt-to-Equity of -0.78 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avivagen and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avivagen's current Debt-to-Equity is -0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current Debt-to-Equity of -0.78. The current Debt-to-Equity is -0.78. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Avivagen (VIVXF), the current Debt-to-Equity is -0.78 as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.